Silke Appel‐Dingemanse

Author

Also Known As

S APPELDINGEMANSE, S Appel-Dingemanse, S. Appel-Dingemanse, S. Appel‐Dingemanse, S. Appel–Dingemanse, Silke Appel-Dingemanse, Silke Appeldingemanse, Silke Appel‐Dingemanse

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Novartis (France)Tris Pharma (United States)Novartis (United Kingdom)

About

Silke Appel‐Dingemanse is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	216
2	Gastroenterology	4	4	85
3	Public Health	1	1	11
4	Social Sciences	1	1	10
5	Immunology	1	1	48

Silke Appel‐Dingemanse

Publications

979

Citations

H-Index

Page 1

	Year	Citations
Tegaserod, a 5‐HT <sub>4</sub> receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects Lukas Degen, Daniel Matzinger, Michael Merz, Alimentary Pharmacology & Therapeutics	2001	208
Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients Gilbert Lefèvre, G Sędek, S. S. Jhee, Clinical Pharmacology & Therapeutics	2007	126
A PHASE I STUDY OF A 4-WEEK COURSE OF SDZ-RAD (RAD) IN QUIESCENT CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS1,2 Barry D. Kahan, Robert Wong, Stephen H. Katz, Transplantation	1999	109
Rivastigmine exposure provided by a transdermal patch versus capsules François Mercier, Gilbert Lefèvre, Hsun‐Lun Aaron Huang, Current Medical Research and Opinion	2007	77
Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects Joel Morganroth, Peter C. Rüegg, Cornelia Dunger‐Baldauf, The American Journal of Gastroenterology	2002	70
Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism Natalie L. Trevaskis, David M. Shackleford, William N. Charman, Pharmaceutical Research Cannabis UseFirst-pass MetabolismIntestinal Lymphatic TransportPost-prandial Oral BioavailabilityFunctional Selectivity	2009	48
Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects Gilbert Lefèvre, F. Pommier, G Sędek, The Journal of Clinical Pharmacology Translational MedicineHealthy Elderly SubjectsPharmacologyTopical DrugPharmacotherapy	2008	44
Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT<sub>4 </sub>receptor agonist, following oral and intravenous administration Silke Appel‐Dingemanse, Marie‐Odile Lemarechal, Anette Kumle, British Journal of Clinical Pharmacology	1999	39
Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety Anne Gardin, Klaus Kucher, Beate Kiese, Drug Metabolism and Disposition	2009	33
RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis Ramona L. Doyle, Marshall I. Hertz, Jordan Dunitz, The Journal of Heart and Lung Transplantation TransplantationAdvanced Lung DiseaseMedicinePulmonary FibrosisPulmonary Medicine	2001	31

Page 1